Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 15958

AbstractMaterial and MethodsResultsDiscussionConclusionAcknowledgementReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"



Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018




Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."



Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018




Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."



Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018




Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."



Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
Lucknow
On Sep 2018




Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."



Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata




Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
Muzaffarnagar.
On Aug 2018




Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".



Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
Bengaluru.
On Aug 2018




Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".



Dr. Mamta Gupta
Consultant
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018




Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.


Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."



Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011




Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."



Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011
Anuradha

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.


Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020

Important Notice

Original article / research
Year : 2022 | Month : November | Volume : 16 | Issue : 11 | Page : KC01 - KC07 Full Version

Metagenomics Comparison of Buruli and Non Buruli Ulcer Skin Wound


Published: November 1, 2022 | DOI: https://doi.org/10.7860/JCDR/2022/57331.17118
Anushka Singh, Ruchi Yadav

1. B.Tech Student, Amity Institute of Biotechnology, Amity University, Lucknow, Uttar Pradesh, India. 2. Assistant Professor, Amity Institute of Biotechnology, Amity University, Lucknow, Uttar Pradesh, India.

Correspondence Address :
Ruchi Yadav,
Malhaur, Near Railway Station, Gomti Nagar Extension, Lucknow-226028, Uttar Pradesh, India.
E-mail: ryadav@lko.amity.edu

Abstract

Introduction: Buruli Ulcer (BU) is caused due to mycobacteria, namely Mycobacterium ulcerans. Buruli ulcer is caused by the mycolactones that are secreted by the Mycobacterium ulcerans which results into the tissue necrosis. Metagenomics is a branch of genomics that deals with the study of uncultured microbial genomes present in natural samples like human body parts, environmental samples, food and dairy, disease conditions. Metagenomics branch has enabled us to explore and elucidate the importance of microbial genomes in healthy and infected samples.

Aim: To evaluate metagenomic and microbial analysis of buruli and non buruli ulcer skin wound samples along with structural and functional analysis of MUL_3720 protein.

Materials and Methods: The present analytical study was conducted from May 2021 to January 2022 at Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, India. European Nucleotide Archive (ENA) database was used to retrieve metagenome data of BU and non BU skin lesions with the project id PRJEB14948. Galaxy server was used for the metagenomics analysis from quality control to identification and classification of microbial community in the samples. Different tools from the Galaxy like FASTQC, Trim Galore, KRAKEN2, convert kraken, Krona pie chart tools were used for metagenomic analysis and for taxonomic classification of microbes. Finally, Krona pie chart was generated that gives an elaborate understanding of the different microbes and their percentage in the BU. Complete annotation like protein structure prediction, domain analysis of MUL_3720 protein of Mycobacterium ulcerans was also done as potential drug target against BU. Statistical analysis was done using Krona pie chart generation and prediction.

Results: Metagenomic analysis shows that there is difference in microbiome of BU and non BU samples. Differential microbes identified were Mycobacteriacae 1-2%, Sporomusa species 18-22% and Desulfovibrio halophillus 24-25%. Bacteria which were present in both the samples are Actiniidae, Desulfovibrio halophillus, Sphingomonas, and Mycobacteriacae. Structural and functional annotation of MUL_3720 protein of Mycobacterium ulcerans shows that MUL_3720 protein can be potential drug target for drug discovery.

Conclusion: This study highlights the metagenome of Buruli Ulcer skin wound and can be used to identify potential drug targets for Buruli Ulcer. Metagenomic analysis of BU and non BU skin wound shows that there is difference in microbial community hence this information can be used in proper diagnostic and medication to combat Buruli Ulcer disease.

Keywords

European nucleotide archive database, Galaxy server, Krona pie chart, Microbiome

Buruli Ulcer (BU) is a deadly skin disease, which can even lead to distortion of limbs (1). It is caused by mycobacteria named Mycobacterium ulcerans it secretes mycolactones which is a toxin and produced by many pathogenic bacteria and by Mycobacterium ulcerans also that results in necrosis of the surrounding tissues and skin lesions (2). Buruli ulcer is one of the most commonly occurring skin infection that is caused by mycobacterial diseases and this infection has higher frequency in the African countries (3). The main body organs or parts that are affected due to this disease are skin and bones (4). In case of improper treatment, major and serious consequences of the disease are permanent or long-term deformity and disability.

The exact mode of transmission of BU in the human population is still not known and it is of important research interests (5). Some hypothesis state that causative bacterium, Mycobacterium ulcerans is transmitted into human population through the aquatic bodies (6). This is essentially based on the disease spreading in regions that are having number of water bodies that are stagnant. Mycobacterium ulcerans generally live independently or is an association with the various other organisms like mosses, faeces of the animal, insects, crayfishes living in the aquatic environment (7).

One of the earliest symptoms of the diseases noted is the appearance of a bump which is swollen and painful (8). Other variable form noted as hard, elevated skin known as plaque, that is spread widely beneath the skin cover (9). After weeks of infection, skin is raised abruptly and then subsequently sloughs out rendering an ulcer which is of painful nature. In some cases, healing of the ulcer on its own has been seen, but sometimes it may decrease in size and remain like an open wound for years (10). In other cases, having larger ulcer, the infection may penetrate deep till the tissue that are lying beneath, causing serious implications like infection of the bone that renders muscles (11).

Medical treatment includes oral rifampin and intramuscular streptomycin or oral administration of rifampin in addition to clarithromycin for about two months which is directed by the World Health Organisation (12). The WHO has classified BU into following three categories:

• Category I- Ulcer which is single in number and spreads across an area of less than 5 cm.
• Category II- Ulcer that are with broader swollen areas and wider in size that is upto 15 cm (13).
• Category III- Ulcer sizing more than 15 cm or who have spread to areas like eyes, genitals, joints, which are highly sensitive area, are included in this group (14).

The drug combination and dosage advised by WHO are rifampicin and clarithromycin to be administered once and twice, respectively on daily basis (15). Other drugs that can be also effective include, levofloxacin, moxifloxacin, amikacin (16). Surgery is also a major part of the treatment process as it can fasten the recovery process by removing the necrotic tissue, in this way it also stops the spreading of the infection to the surrounding areas (17).

Prevention is better than cure and this deadly disease can be prevented by trying to avoid coming in close contact with the water bodies (18). However, this situation is unavoidable by the people living in these areas (19). Wearing clothes with full length or long sleeves and using mosquito repellents can be effective preventive measures. Till now, no vaccine has been designated but Bacille Calmette-Guérin (BCG) vaccine has been found to be partly effective in dealing with this disease (20). The specific mode of transmission of BU is still into research but it mostly takes place in regions around waterways that are stale or stagnant and slow moving. It has been seen that cases rise in the rainy seasons (21). The bites from mosquitoes have been proposed as a mode of transmission relying the on epidemiologic examination that were conducted during Australian outbreak (22).

Metagenomics is compiled from two words “Meta” and “Genomics”. It basically refers to the study and examination of genetic material of the samples that are obtained from the environment. Metagenomics has tremendous capability to reveal the hidden or the undiscovered microorganisms (23). Metagenomics is designated as the study of genetic materials of different natural samples that are collected from the environment like soil, water, plants, food, organ (24). Metagenomics can reveal the varieties and hidden potentials of microscopic organisms, so that the understanding of the living world is revolutionised (25). Metagenomics has enabled researchers to study and identify novel microbes that are present in different conditions. Metagenomic holds great promise in revealing microbes, their genes, and pathways that have function in different environmental, biological or any condition of interest (26). Since, decades bioinformatics has been used to reveal the hidden function of genes, proteins, upto genome and proteome level (27). MUL_3720, a M. ulcerans protein, is a promising target for antigen capture-based detection methods. Currently the power of computational biology and sophisticated software’s has enabled researchers to analyse high throughput data generated from Next Generation Sequencing (NGS) (28). This capability of bioinformatics has been explored in metagenomics also to identify the microbes present in metagenome sequence data. With the availability of bioinformatics tools and software’s metagenomics study holds great potential in identification of microbial community in specific microbiomes (29). Hence, the present study aimed to evaluate metagenomics analysis of BU samples and identified microbiome in BU. Structural and functional analysis of MUL_3720 was also done that can be used as drug target.

Material and Methods

The present analytical study was conducted from May 2021 to January 2022 at Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, India.

Retrieval of the metagenomic data: Bioinformatics database that is European Nucleotide Archive (ENA) database (https://www.ebi.ac.uk/ena/browser/) was used to download metagenome data of BU. The raw data of BU was retrieved from ENA database with the project id PRJEB14948 (https://www.ebi.ac.uk/ena/browser/view/PRJEB14948?show=reads). Complete experimental information and data generation protocol can be accessed from project id PRJEB14948 and link provided above. This data contains six samples from a BU skin wound and seven samples from a non BU skin wound. In this project Illumina MiSeq paired end sequencing was performed to get metagenome of both types of samples. Total four files were selected for current research and two conditions were made namely:

1: Non Buruli Ulcer skin wound
2: Buruli Ulcer skin wound

Details of sample files used has been shown in (Table/Fig 1) along with their accession ID, sample type and conditions.

Metagenomics tools: Metagenomics tools used for this study were used from the Galaxy Server (https://metagenomics.usegalaxy.eu/). Different tools were used for data preprocessing, quality control analysis, taxonomic classification, and visualisation of metagenome (30). (Table/Fig 2) lists all the tools along with their functions that were used for metagenomics analysis of data sets (31),(32),(33),(34),(35).

Metagenomics Analysis Protocol

i) Quality control: It is procedure to check and manage the data quality. It is an important step for obtaining high quality output data in the results. It is executed for precision, fulfilment, relevance, legitimacy, practicality, and consistency of the information (36). To perform quality control analysis of the uploaded FASTQ file. Firstly, authors searched for the FASTQC tool from the galaxy tool panel. FASTQC was performed for all sample files. (Table/Fig 3) shows the steps and tools used for this study.
ii) Data preprocessing: It is important step to filter all adapter sequence or contaminants from the FASTQ files. This step was performed using Trim Galore tool from the galaxy tool panel. Trim Galore tool was searched from the galaxy tool panel. FASTQC output file was used as input file in Trim Galore tool. Result of Trim Galore tool appeared in the history column of the galaxy (37).
iii) Taxonomic classification: Kraken 2 is the latest version of Kraken tool. It is a tool for taxonomic classification, and it works by using exact k-mer matches with the microbial database for obtaining accurately and speedy classification. KRAKEN 2 tool was searched from the galaxy tool panel. Trim Galore output files were used as input in Kraken 2 tool. The result of KRAKEN 2 was appeared in the history column of the galaxy (38).
iv) Taxonomic representation: KRAKEN 2 result file was converted into galaxy readable representation format so that data can be visualised. This step was performed using Convert kraken tool in this tool output of Kraken 2 tool was used as input and formatted file was obtained (39).
v) Metagenomic visualisation: To obtain the clubbed metagenomic results in a pie chart form, Krona pie chart tool was used. In this tool results of Convert Kraken were used as input and pie chart was obtained for all the samples (40).

Functional annotation of MUL_3720 protein of Mycobacterium ulcerans as drug target: Further to investigate the target protein of Mycobacterium ulcerans MUL_3720 protein was selected. Bioinformatics tools like Swiss model server was used to predict the structure of target protein. Structure prediction is important to understand the function and prediction of active sites, binding regions of protein. To study the function of MUL_3720, domain prediction was done. Domain prediction is very crucial part of protein function identification, as domain is a part of protein that is functionally and structurally conserved (41).

Further to highlight the importance of MUL_3720 protein docking was performed to study the efficiency of interaction of target protein with drug. Docking is a computational method that is used to predict the interaction of protein with any ligand, drug or any chemical compound of interest (42). In current study, docking of MUL_3720 with rifampicin drug was done to access the suitability of MUL_3720 as target protein. MUL_3720 protein sequence information was retrieved from UniProtKB database https://www.uniprot.org/uniprot/A0PU23#sequences. UniProtKB-A0PU23 (A0PU23_MYCUA). All functional annotation to docking analysis has been described in result section.

Statistical Analysis

Statistical analysis was done using Krona pie chart generation and prediction. The data has been tabulated in the form of percentages.

Results

Metagenomics analysis of BU and Non BU: Metagenomics analysis of all the sample files was done using methodology and tools as mentioned in (Table/Fig 3). All files passed the Quality Control (QC) and trimming was done in all four files. After QC and data preprocessing analysis was done. Results were compiled in the form of Krona pie chart which shows the various microorganisms that were present in all the samples. Krona pie chart for the set 1 i.e., sample from the non BU is depicted in the (Table/Fig 4), which shows the bacterial diversity and classification along with their percentage composition.

Similarly, the final results for the set two data i.e., sample from the Bururli Ulcer was shown in (Table/Fig 5), where bacterial pie chart shows relatively higher concentration of Sphingomonas species about 42% which is evident from the krona pie chart.

Bacterial diversity in both the conditions non BU skin wound (ERR1551328 and ERR1551330) and BU skin wound (ERR1551321 and ERR1551322) were studied and results were compared. (Table/Fig 6) shows the comparison between bacteria in both the conditions. The bacteria which were present in both non BU and BU skin wound are Actiniidae, Desulfovibrio halophillus, Sphingomonas and Mycobacteriacae. Bacteria which were present only in Buruli ulcer skin wound are Cyanothece species, Thermosipho melanesiensis, Streptosporangium longisporum, Massilia timonae as seen in (Table/Fig 4), (Table/Fig 5).

Metagenomics analysis of BU shows that there is difference in microbial community in BU and Non BU skin disease. Metagenomics analysis shows percentage of microbes in the BU that is Mycobacteriacae about 1-2%, Sporomusa species about 18-22%, Desulfovibrio halophilus about 24-25% etc. Bacteria which are present in both the samples were Actiniidae, Desulfovibrio halophilus, Sphingomonas, and Mycobacteriacae. This study can be used to identify potential drug targets for BU.

Annotation of MUL_3720 protein of Mycobacterium ulcerans as drug target: Protein annotation is a important approach to study the function of protein. With the help of bioinformatics tools and software’s protein structure and function prediction can be done. MUL_3720 protein of Mycobacterium ulcerans was annotated and its function was studied using computational methods. MUL_3720 protein sequence information was retrieved from UniProtKB database https://www.uniprot.org/uniprot/A0PU23#sequences. Domain is functional part of protein that is conserved in structure and function across protein family and superfamily. Protein functional sites that are called as motifs are also important to predict the protein function. Multiple motifs make domain hence domain identification is a important parameter to identify protein function. Any novel protein function can be predicted with the help of domain identification (43). UniProtKB-A0PU23 (A0PU23_MYCUA) protein sequence was used for domain identification, structure prediction and structural analysis. MUL_3720 protein was extensively studied as potential drug target against Mycobacterium ulcerans causing BU.

Domain identification of MUL_3720 protein was done using Scan Prosite tool it is online tool available at (https://prosite.expasy.org/scanprosite/) and protein functional regions that is domains were identified. (Table/Fig 7) shows the domain information of MUL_3720 protein (44),(45). Two domains BULB_LECTIN (Bulb-type lectin domain profile) and LYSM with profile id PS50927and PS51782 respectively were predicted, and function was studied. BULB_LECTIN domain was identified from protein sequence position 2-109 and LYSM domain was predicted from protein sequence position from 159-206.

Protein structure prediction: MUL_3720 protein structure prediction was done by homology modelling method (46). Homology modelling is computational technique that can be used to predict the structure of protein of unknown protein structure. Since all proteins cannot be crystallised hence structure of all proteins are unavailable. Homology modelling method predicts the structure of protein based on sequence homology. If sequence homology is more than 30% this method can be used to predict protein structure. Homology modelling works on the assumption that homologous sequence has similar structure (47). Homology modelling of MUL_3720 was done using Swiss model server https://swissmodel.expasy.org/.

First step in homology modelling is to identify homologous sequence called as template. Template sequences have sequence similarity with the MUL_3720 protein and structure is known. Template with PDB id 4oit.2. A was identified for homology modelling of MUL_3720 protein with the sequence homology of 77.14%. Template used for structure prediction have LysM domain protein structure of Mycobacterium smegmatis. (Table/Fig 8) shows the three-dimensional structure of MUL_3720 protein of Mycobacterium ulcerans.

Structural verification and validation are important aspect of protein structure prediction. Different methods are available that verifies the computationally predicted protein structure. Out of these methods Ramachandran plot analysis method is best to verify any protein structure (48). It plots protein amino acids in four regions as shown in (Table/Fig 9) and locates amino acids according to their phi and psi angles. Ramachandran plot amino acids as favourable region (dark green), left handed alpha helix regions (light green) and disallowed regions (white) (49). Ramachandran plot analysis was done for predicted protein structure of MUL_3720 for structural verification and quality assessment as shown in (Table/Fig 9). According to Ramachandran plot 96.08% residues lies in favoured and 0.0% in Outlier’s region. Structural analysis shows that predicted structure is stable and can be further used for binding site prediction and analysis.

Docking of MUL_3720 with rifampicin: Docking is yet another and most widely used computational method to predict the interaction between protein and ligands, drugs. Docking can be used to study the binding efficiency, stable or unstable interaction, binding energy hence stability of interaction between any two molecules of interest. Docking can be used to predict protein-drug interaction, protein-protein interaction, DNA-protein interaction etc (50). Docking method was used in current research to study the efficiency of MUL_3720 protein as potential drug target. Hence, MUL_3720 protein was docked with known drug that is Rifampicin to study the binding efficiency of target protein. Binding site prediction and interaction with drug analysis of predicted protein structure was done using docking (51). Rifampicin drug that is well known and established drug for Buruli Ulcer was used for docking. Rifampicin drug file and structural information was retrieved from PubChem database with CID 135398735 having chemical formulae as C43H58N4O12 as shown in (Table/Fig 10).

The MUL_3720 Protein interaction with Rifampicin drug was done by docking method using CB-Dock server which is a Cavity-detection guided Blind Docking server (52). (Table/Fig 11) shows the interaction of Rifampicin drug with target protein. Docking result shows that MUL_3720 protein have binding efficiency with Rifampicin drug with the vina score of -7.1 and cavity size of 215.

Structural and functional annotation of MUL_3720 protein of Mycobacterium ulcerans shows that MUL_3720 protein can be potential drug target for drug discovery. Domain analysis shows that MUL_3720 protein have function in BU, structural and docking analysis shows that this protein has binding efficiency towards drug as docking was done with rifampicin drug.

Discussion

Metagenomics analysis has become the important tool to understand the microbial community in different biomes like soil, water, plants, animals, organ, or organ system. Metagenomics approach has been used to study the microbial diversity along with their percentage in different disease condition like gut cancer, skin cancer, liver infection, mouth, or oral cancer. Metagenomics tools has been used to identify infections in cardiovascular disease (53), oral health condition, infectious diseases (54), gut viromes, colorectal cancer (55), autoimmune diseases (56). In current research, metagenome analysis was done to predict the microbial community in BU and non BU. Researches has been done BU skin wound to study the protein or genes involved in BU skin (57). But with the advent of metagenomics, it is possible to explore the presence of microbes in such condition that can be further used for medicinal or clinical purposes. In current research metagenomics analysis of non BU skin wound and BU skin wound was done by using metagenome data from metagenome databases. Complete and exhaustive analysis of BU metagenome shows that there is difference in microbiomes of both the condition of skin wound. This study highlights the important microorganisms shows their presence only in Buruli ulcer skin wound. The microbiome of BU skin wound showed presence of Cyanothece, Thermosipho melaneiensis, Streptosporangium longisporum, Massilia timonae. Metagenomics analysis shows percentage of microbes in the BU that is Mycobacteriacae about 1-2%, Sporomusa species about 18-22%, and Desulfovibrio halophilus about 24-25%. Bacteria which are present in both the samples were Actiniidae, Desulfovibrio halophilus, Sphingomonas, and Mycobacteriacae. This study can be used to identify potential drug targets for BU. Further complete annotation of MUL_3720 protein of Mycobacterium ulcerans was done to study the efficiency of MUL_3720 protein as potential drug target. Structural and functional analysis shows that MUL_3720 protein can be potential drug target and can be used for drug discovery.

Limitation(s)

The present study was completely based on computational approach with the help of well established and verified protocol. This research gives insights into the metagenome of BU and non BU skin wound and highlights the presence of bacteria in both the condition. But clinical and microbial investigation is required to further investigate the microbial community in BU condition.

Conclusion

Metagenomic analysis of BU and non BU skin wound shows that there is difference in microbial community in both the conditions. More information is still required to combat this disease as there is lack in greater and deeper knowledge about the deadly diseases like BU. Proper medication is the need of the hour to combat this disease. Hence, more research and investigation are required about the metagenome, protein function of BU. Development of control and prevention strategies also requires equal attention, which provides great opportunities to leverage new and latest diagnosis. Mycolactones secreted by the Mycobacteria ulcerans is a toxin which can be used in various research fields if investigated thoroughly. Hence, BU holds a lot of scope of research not only in the field of medication but also in understanding the cause and mechanism of action these bacteria and also they can be employed various sectors in the ever changing and the revolutionising world.

Acknowledgement

Authors would like to acknowledge Amity Institute of Biotechnology, Amity University, Uttar Pradesh, Lucknow campus for providing the facilities to conducting the study.

References

1.
Yotsu RR, Suzuki K, Simmonds RE, Bedimo R, Ablordey A, Yeboah-Manu D, et al. Buruli ulcer: A review of the current knowledge. Current tropical medicine reports. 2018;5(4):247-56. [crossref] [PubMed]
2.
Dhungel L, Benbow ME, Jordan HR. Linking the Mycobacterium ulcerans environment to Buruli ulcer disease: Progress and challenges. One Health. 2021;13:100311. [crossref] [PubMed]
3.
Scherr N, Bieri R, Thomas SS, Chauffour A, Kalia NP, Schneide P, et al. Targeting the Mycobacterium ulcerans cytochrome bc1: aa3 for the treatment of Buruli ulcer. Nat Commun. 2018;9(1):5370. [crossref] [PubMed]
4.
Muleta AJ, Lappan R, Stinear TP, Greening C. Understanding the transmission of Mycobacterium ulcerans: A step towards controlling Buruli ulce. PLoS Neglected Tropical Diseases. 2021;15(8):e0009678. [crossref] [PubMed]
5.
Zingue D, Bouam A, Tian RB, Drancourt M. Buruli ulcer, a prototype for ecosystem-related infection, caused by Mycobacterium ulcerans. Clinical microbiology reviews.2018;e00045:17. [crossref] [PubMed]
6.
Djouaka R, Zeukeng F, Bigoga JD, Kakou-Ngazoa SE, Akoton R, Tchigossou G, et al. Domestic animals infected with Mycobacterium ulcerans-Implications for transmission to humans. PLoS neglected tropical diseases. 2018;12(7):e0006572. [crossref] [PubMed]
7.
Hammoudi N, Cassagne C, Million M, Ranque S, Kabore O, Drancourt M, et al. Investigation of skin microbiota reveals Mycobacterium ulcerans-Aspergillus sp. trans-kingdom communication. Scientific reports. 2021;11(1):01-09. [crossref] [PubMed]
8.
Yotsu RR, Richardson M, Ishii N. Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). Cochrane Database Syst Rev. 2018;8(8):CD012118. [crossref] [PubMed]
9.
Chen YE, Fischbach MA, Belkaid Y. Skin microbiota-host interactions. Nature. 2018;553(7689):427-36. [crossref] [PubMed]
10.
Röltgen K, Pluschke G. Buruli ulcer: The efficacy of innate immune defense may be a key determinant for the outcome of infection with Mycobacterium ulcerans.Frontiers in Microbiology. 2020;11:1018. [crossref] [PubMed]
11.
Receveur JP, Bauer A, Pechal JL, Picq S, Dogbe M, Jordan HR, et al. A need for null models in understanding disease transmission: The example of Mycobacterium ulcerans (Buruli ulcer disease). FEMS Microbiol Rev. 2022;46(1):fuab045. [crossref] [PubMed]
12.
Maman I, Tchacondo T, Kere AB, Beissner M, Badziklou K, Tedihou E, et al. Molecular detection of Mycobacterium ulcerans in the environment and its relationship with Buruli ulcer occurrence in Zio and Yoto districts of maritime region in Togo. PLoS neglected tropical diseases. 2018;12(5):e0006455. [crossref] [PubMed]
13.
Zingue D, Panda A, Drancourt M. A protocol for culturing environmental strains of the Buruli ulcer agent, Mycobacterium ulcerans. Scientific reports. 2018;8(1):01-02. [crossref] [PubMed]
14.
Gao Y, Hameed HA, Liu Y, Guo L, Fang C, Tian X, et al. Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance for Mycobacterium ulcerans. Acta Pharmaceutica Sinica B. 2021;11(3):738-49. [crossref] [PubMed]
15.
Combe M, Gozlan RE, Jagadesh S, Velvin CJ, Ruffine R, Demar MP, et al. Comparison of Mycobacterium ulcerans (Buruli ulcer) and Leptospira sp.(Leptospirosis) dynamics in urban and rural settings. PLoS neglected tropical diseases. 2019;13(1):e0007074. [crossref] [PubMed]
16.
Anagonou EG, Johnson RC, Barogui YT, Sopoh GE, Ayelo GA, Wadagni AC, et al. Decrease in Mycobacterium ulcerans disease (Buruli ulcer) in the Lalo District of Bénin (west Africa). BMC Infectious Diseases. 2019;19(1):01-07. [crossref] [PubMed]
17.
Coudereau C, Besnard A, Robbe-Saule M, Bris C, Kempf M, Johnson RC, et al. Stable and local reservoirs of Mycobacterium ulcerans inferred from the nonrandom distribution of bacterial genotypes. Benin. Emerging infectious diseases. 2020;26(3):491. [crossref] [PubMed]
18.
Demangel C. Immunity against Mycobacterium ulcerans: The subversive role of mycolactone. Immunological reviews. 2021;301(1):209-21. [crossref] [PubMed]
19.
Hammoudi N, Dizoe S, Saad J, Ehouman E, Davoust B, Drancourt M, et al. Tracing Mycobacterium ulcerans along an alimentary chain in CĂ´te d’Ivoire: A one health perspective. PLoS Negl Trop Dis. 2020;14(5):e0008228. [crossref] [PubMed]
20.
Nain Z, Karim MM, Sen MK, Adhikari UK. Structural basis and designing of peptide vaccine using PE-PGRS family protein of Mycobacterium ulcerans-An integrated vaccinomics approach. Molecular Immunology. 2020;120:146-63. [crossref] [PubMed]
21.
Yerramilli A, Tay EL, Stewardson AJ, Fyfe J, O’Brien DP, Johnson PD. The association of rainfall and Buruli ulcer in southeastern Australia. PLoS neglected tropical diseases. 2018;12(9):e0006757. [crossref] [PubMed]
22.
Kpeli GS, Yeboah-Manu D. Secondary infection of Buruli ulcer lesions. Buruli Ulcer: Mycobacterium ulcerans Disease. Cham. 2019;29:227-39. [crossref] [PubMed]
23.
Converse PJ, Almeida DV, Tyagi S, Xu J, Nuermberger EL. Shortening Buruli ulcer treatment with combination therapy targeting the respiratory chain and exploiting Mycobacterium ulcerans gene decay. Antimicrobial agents and chemotherapy. 2019;63(7):e00426-19. [crossref] [PubMed]
24.
Phillips RO, Robert J, Abass KM, Thompson W, Sarfo FS, Wilson T, et al. Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: A randomised, open-label, non-inferiority phase 3 trial. The Lancet. 2020;395(10232):1259-67. [crossref] [PubMed]
25.
O’Brien DP, Friedman ND, Walton A, Hughes A, Athan E. Risk factors associated with antibiotic treatment failure of Buruli ulcer. Antimicrobial Agents and Chemotherapy. 2022;64(9):e00722-20. [crossref] [PubMed]
26.
Chiu CY, Miller SA. Clinical metagenomics. Nature Reviews Genetics. 2019;20(6):341-55. [crossref] [PubMed]
27.
Greninger AL. The challenge of diagnostic metagenomics. Expert review of molecular diagnostics. 2018;18(7):605-15. [crossref] [PubMed]
28.
Simon HY, Siddle KJ, Park DJ, Sabeti PC. Benchmarking metagenomics tools for taxonomic classification. 2019;178(4):779-94. [crossref] [PubMed]
29.
Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJ. Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data. Microbiome. 2018;6(1):01-04. [crossref] [PubMed]
30.
Deep U, Yadav R. Motif prediction of abemaciclib in a breast cancer cell line using ChIP-Seq data analysis. Biomedical Research and Therapy. 2022;9(3):4971-85. [crossref]
31.
Jain M, Yadav R. Metagenomics analysis of breast cancer to study bacterial diversity. Journal of Drug Delivery and Therapeutics. 2022;12(2-S):119-26. [crossref]
32.
Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2. Genome biology. 2019;20(1):01-03. [crossref] [PubMed]
33.
Wood DE, Salzberg SL. “Kraken: Ultrafast metagenomic sequence classification using exact alignments”. Genome Biology. 2014;15(3):01-02. [crossref] [PubMed]
34.
Liu YX, Qin Y, Chen T, Lu M, Qian X, Guo X, et al. A practical guide to amplicon and metagenomic analysis of microbiome data. Protein & cell. 2021;12(5):315-30. [crossref] [PubMed]
35.
D’Agostino D, Morganti L, Corni E, Cesini D, Merelli I. Combining edge and cloud computing for low-power, cost-effective metagenomics analysis. Future Generation Computer Systems. 2019;90:79-85. [crossref]
36.
Maran MI. “Benefits of merging paired-end reads before pre-processing environmental metagenomics data”. Marine Genomics. 2022;61:100914. [crossref] [PubMed]
37.
Anyaso-Samuel S, Sachdeva A, Guha S, Datta S. Bioinformatics pre-processing of microbiome data with an application to metagenomic forensics. InStatistical Analysis of Microbiome Data. Springer, Cham. 2021;45-78. [crossref]
38.
Sala C, Mordhorst H, Grützke J, Brinkmann A, Petersen TN, Poulsen C, et al. Metagenomics-based proficiency test of smoked salmon spiked with a mock community. Microorganisms. 2020;8(12):1861. [crossref] [PubMed]
39.
Allali I, Abotsi RE, Tow LA, Thabane L, Zar HJ, Mulder NM, et al. Human microbiota research in Africa: A systematic review reveals gaps and priorities for future research. Microbiome. 2021;9(1):01-54. [crossref] [PubMed]
40.
Umer N, Naqvi RZ, Rauf I, Anjum N, Keen PR, Van Eck J, et al. Expression of Pinellia ternata leaf agglutinin under rolC promoter confers resistance against a phytophagous sap sucking aphid, Myzus persicae. Electronic Journal of Biotechnology. 2022;47:72-82. [crossref]
41.
Li X, Song Y. Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins. Journal of Hematology & Oncology. 2021;14(1):01-33. [crossref] [PubMed]
42.
Stanzione F, Giangreco I, Cole JC. Use of molecular docking computational tools in drug discovery. Progress in Medicinal Chemistry. 2021;60:273-43. [crossref] [PubMed]
43.
Rohaim MA, El Naggar RF, Clayton E, Munir M. Structural and functional insights into non-structural proteins of coronaviruses. Microbial pathogenesis. 2021;150:104641. [crossref] [PubMed]
44.
Dhungel L, Burcham L, Park JY, Sampathkumar HD, Cudjoe A, Seo KS, et al. Responses to chemical cross-talk between the Mycobacterium ulcerans toxin, mycolactone, and Staphylococcus aureus. Scientific reports. 2021;11(1):01-02. [crossref] [PubMed]
45.
Oguiza JA. LysM proteins in mammalian fungal pathogens. Fungal Biology Reviews. Fungal biology reviews. 2022;40:14-122. [crossref]
46.
Yadav R. Elucidating structural, functional and phylogenetic relationship of large envelope protein of hepatitis B virus. Indian Journal of Science and Technology. 2022;15(10):451-56. [crossref]
47.
Bhunia SS, Saxena AK. Efficiency of homology modeling assisted molecular docking in G-protein coupled receptors. Current Topics in Medicinal Chemistry. 2021;21(4):269-94. [crossref] [PubMed]
48.
Mahrosh HS, Mustafa G. An in silico approach to target RNA-dependent RNA polymerase of COVID-19 with naturally occurring phytochemicals. Environment, Development and Sustainability. 2021;23(11):16674-87. [crossref] [PubMed]
49.
Swargiary A, Mahmud S, Saleh MA. Screening of phytochemicals as potent inhibitor of 3-chymotrypsin and papain-like proteases of SARS-CoV2: An in silico approach to combat COVID-19. Journal of Biomolecular Structure and Dynamics. 2022;40(5):2067-81. [crossref] [PubMed]
50.
Soni K, Yadav R. Virtual screening and molecular docking study to identify novel inhibitors against Japanese encephalitis virus. Int J Cur Res Rev. 2021;13(13):168. [crossref]
52.
Yadav R. Astrotactin-2: Docking with flavoinoids, functional, pathway and disease associations. Current Trends in Biotechnology and Pharmacy. 31,15, 2,189-97, 2021 May.
52.
Tejaswini AV, Malothu R. Molecular docking and MD simulation analysis of L-asparaginase of Streptomyces iranensis, Streptomyces himalayensis and Streptomyces griseus. Current Trends in Biotechnology and Pharmacy. 2021;15(4):390-400.
53.
Alcaraz LD, Belda-Ferre P, Cabrera-Rubio R, Romero H, Simón-Soro A, Pignatelli M, et al. Identifying a healthy oral microbiome through metagenomics. Clin Microbiol Infect. 2012;18:54-57. [crossref] [PubMed]
54.
d’Humières C, Salmona M, Dellière S, Leo S, Rodriguez C, Angebault C, et al. The potential role of clinical metagenomics in infectious diseases: Therapeutic perspectives. Drugs. 2021;81(13):1453-66. [crossref] [PubMed]
55.
Ng C, Li H, Wu WK, Wong SH, Yu J. Genomics and metagenomics of colorectal cancer. Journal of Gastrointestinal Oncology. 2019;10(6):1164. [crossref] [PubMed]
56.
Proal AD, Albert PJ, Marshall T. Autoimmune disease in the era of the metagenome. Autoimmunity reviews. 2009;8(8):677-81. [crossref] [PubMed]
57.
Bahadoran P, Hammoudi N, Gaudart A, Saad J, Di Filippo Y, Drancourt M, et al. Case report: A new Mycobacterium ulcerans genotype causing buruli ulcer in CĂ´te d’Ivoire. The American Journal of Tropical Medicine and Hygiene. 2021;104(5):1782. [crossref] [PubMed]

DOI and Others

DOI: 10.7860/JCDR/2022/57331.17118

Date of Submission: Apr 26, 2022
Date of Peer Review: Jul 01, 2022
Date of Acceptance: Aug 29, 2022
Date of Publishing: Nov 01, 2022

AUTHOR DECLARATION:
• Financial or Other Competing Interests: None
• Was Ethics Committee Approval obtained for this study? No
• Was informed consent obtained from the subjects involved in the study? No
• For any images presented appropriate consent has been obtained from the subjects. No

PLAGIARISM CHECKING METHODS:
• Plagiarism X-checker: May 02, 2022
• Manual Googling: Aug 22, 2022
• iThenticate Software: Aug 27, 2022 (5%)

ETYMOLOGY: Author Origin

JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)
  • www.omnimedicalsearch.com